Anatomical location of urothelial carcinomas of the urinary tract leads to perspectives of specific treatment

Future Oncology

Volumn 3, Issue 6, 2007, Pages 595-599

  Rouprêt, Morgan ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; ANTINEOPLASTIC AGENT; AROMATIC AMINE; BENZIDINE; CHINESE DRUG; CYCLOOXYGENASE 2 INHIBITOR; DNA; HERBACEOUS AGENT; NAPHTHYLAMINE; PHENACETIN; POLYCYCLIC AROMATIC HYDROCARBON; PROTEIN P53; SULFOTRANSFERASE; TOBACCO SMOKE; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; BLADDER CARCINOMA; CANCER ADJUVANT THERAPY; CANCER GENETICS; CANCER LOCALIZATION; CANCER RISK; CANCER SUSCEPTIBILITY; CANCER THERAPY; CARCINOGENESIS; CLONAL VARIATION; COLORECTAL ADENOMA; COLORECTAL CANCER; DRUG SENSITIVITY; EDITORIAL; GENETIC POLYMORPHISM; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENOTYPE PHENOTYPE CORRELATION; GERMINAL CENTER; HUMAN; KIDNEY CARCINOMA; MICROSATELLITE INSTABILITY; MOLECULAR GENETICS; MUTATIONAL ANALYSIS; PRIORITY JOURNAL; TRANSITIONAL CELL CARCINOMA; TREATMENT PLANNING; URETER CARCINOMA; URETHRA CARCINOMA; URINARY TRACT CARCINOMA; UROGENITAL TRACT CANCER;

HUMANS; TUMOR MARKERS, BIOLOGICAL; UROLOGIC NEOPLASMS; UROTHELIUM;

EID: 38049129096     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/14796694.3.6.595     Document Type: Editorial

References (39)

1. Kogevinas M, 't Mannetje A, Cordier S et al.: Occupation and bladder cancer among men in Western Europe. Cancer Causes Control 14(10), 907-914 (2003).
2. Kirkali Z, Chan T, Manoharan M et al.: Bladder cancer: epidemiology, staging and grading, and diagnosis. Urology 66(6 Suppl. 1), 4-34 (2005).
3. Hall MC, Womack S, Sagalowsky AI et al.: Prognostic factors, recurrence, and survival in transitional cell carcinoma of the upper urinary tract: a 30-year experience in 252 patients. Urology 52(4), 594-601 (1998).
4. Roupret M, Catto J, Coolet F et al.: Microsatellite instability as indicator of MSH2 gene mutation in patients with upper urinary tract transitional cell carcinoma, J. Med. Genet. 41(7), E91 (2004).
5. Miyake H, Hara I, Kamidono S, Eto H: Multifocal transitional cell carcinoma of the bladder and upper urinary tract: molecular screening of clonal origin by characterizing CD44 alternative splicing patterns. J. Urol. 172(3), 1127-1129 (2004).
6. Harris AL, Neal DE: Bladder cancer: field versus clonal origin. N. Engl. J. Med. 326(11), 759-761 (1992).
7. Sidransky D, Frost P, Von Eschenbach A et al.: Clonal origin bladder cancer. N. Engl. J. Med. 326(11), 737-740 (1992).
8. Jones TD, Wang M, Eble JN et al.: Molecular evidence supporting field effect in urothelial carcinogenesis. Clin. Cancer Res. 11(18), 6512-6519 (2005).
9. Simon R, Eltze E, Schafer KL et al.: Cytogenetic analysis of multifocal bladder cancer supports a monoclonal origin and intraepithelial spread of tumor cells. Cancer Res. 61(1), 355-362 (2001).
10. Luis NM, Lopez-Knowles E, Real FX: Molecular biology of bladder cancer. Clin. Thansl. Oncol. 9(1), 5-12 (2007).
11. Denzinger S, Mohren K, Knuechel R et al.: Improved clonality analysis of multifocal bladder tumors by combination of histopathologic organ mapping, loss of heterozygosity, fluorescence in situ hybridization, and p53 analyses. Hum. Pathol. 37(2), 143-151 (2006).
12. Stoehr R, Knuechel R, Boecker J et al.: Histologic-genetic mapping by allele-specific PCR reveals intraurothelial spread of p53 mutant tumor clones. Lab. Invest. 82(11), 1553-1561 (2002).
13. Liang FX, Bosland MC, Huang H et al.: Cellular basis of urothelial squamous metaplasia: roles of lineage heterogeneity and cell replacement. J. Cell Biol. 171(5), 835-844 (2005).
14. de la Chapelle A: Microsatellite instability. N. Engl. J. Med. 349(3), 209-210 (2003).
15. Lynch HT, de la Chapelle A: Hereditary colorectal cancer. N. Engl. J. Med. 348(10), 919-932 (2003).
16. Watson P, Lynch HT: The tumor spectrum in HNPCC. Anticancer Res. 14(4B), 1635-1639 (1994).
17. Muller A, Beckmann C, Westphal G et al.: Prevalence of the mismatch-repair-deficient phenotype in colonic adenomas arising in HNPCC patients: results of a 5-year follow-up study. Int. J. Colorectal Dis. 21(7), 632-641 (2006).
18. Hartmann A, Zanardo L, Bocker-Edmonston T et al.: Frequent microsatellite instability in sporadic tumors of the upper urinary tract. Cancer Res. 62(23), 6796-6802 (2002).
19. Bonnal C, Ravery V, Toublanc M et al.: Absence of microsatellite instability in transitional cell carcinoma of the bladder. Urology 55(2), 287-291 (2000).
20. Amira N, Rivet J, Soliman H et al.: Microsatellite instability in urothelial carcinoma of the upper urinary tract. J. Urol. 170(4 Pt 1), 1151-1154 (2003).
21. Catto JW, Azzouzi AR, Rehman I et al.: Promoter hypermethylation is associated with tumor location, stage, and subsequent progression in transitional cell carcinoma. J. Clin. Oncol. 23(13), 2903-2910 (2005).
22. Catto JW, Azzouzi AR, Amira N et al.: Distinct patterns of microsatellite instability are seen in tumors of the urinary tract. Oncogene 22(54), 8699-8706 (2003).
23. Lynch HT Boland CR, Rodriguez-Bigas MA et al.: Who should be sent for genetic testing in hereditary colorectal cancer syndromes? J. Clin. Oncol. 25(23), 3534-3542 (2007).
24. Lynch HT: Family information service and hereditary cancer. Cancer 91(4), 625-628 (2001).
25. Roupret M, Fromont G, Azzouzi AR et al.: Microsatellite instability as predictor of survival in patients with invasive upper urinary tract transitional cell carcinoma. Urology 65(6), 1233-1237 (2005).
26. Roupret M, Hupertan V, Traxer O et al.: Comparison of open nephroureterectomy and ureteroscopic and percutaneous management of upper urinary tract transitional cell carcinoma. Urology 67(6), 1181-1187 (2006).
27. Ribic CM, Sargent DJ, Moore MJ et al.: Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N. Engl. J. Med. 349(3), 247-257 (2003).
28. Thompson IM, Peek M, Rodriguez FR: The impact of cigarette smoking on stage, grade and number of recurrences of transitional cell carcinoma of the bladder. J. Urol. 137(3), 401-403 (1987).
29. Veys CA: ABC of work related disorders. Occupational cancers. Br. Med. J. 313(7057), 615-619 (1996).
30. Linet MS, Chow WH, McLaughlin JK et al.: Analgesics and cancers of the renal pelvis and ureter. Int. J. Cancer 62(1), 15-18 (1995).
31. Laing C, Hamour S, Sheaff M, Miller R, Woolfson R: Chinese herbal uropathy and nephropathy. Lancet 368(9532), 338 (2006).
32. Grollman AP, Shiburani S, Moriya M et al.: Aristolochic acid and the etiology of endemic (Balkan) nephropathy. Proc. Natl. Acad. Sci. USA 104(29),12129-12134 (2007).
33. Nortier JL, Martinez MC, Schmeiser HH et al.: Urothefial carcinoma associated with the use of a Chinese herb (Aristolochia fangchi). N. Engl. J. Med. 342(23), 1686-1692 (2000).
34. Gold LS, Slone TH: Aristolochic acid, an herbal carcinogen, sold on the Web after FDA alert. N. Engl. J. Med. 349(16), 1576-1577(2003).
35. Tsukino H, Kuroda Y, Nakao H et al.: Cytochrome P450 (CYP) 1A2, sulfotransferase (SULT) 1A1, and N-acetyltransferase (SULT) 2 polymorphisms and susceptibility to urothelial cancer. J. Cancer Res. Clin. Oncol. 130(2), 99-106 (2004).
36. Roupret M, Cancel-Tassin G, Comperat E et al.: Phenol Sulfotransferase SULT1A1*2 allele and enhanced risk of upper urinary tract urothdial cell carcinoma. Cancer Epidemiol. Biomarkers Prev. (2007) (In Press).
37. Coughtrie MW. Sulfation through the looking glass: recent advances in sulfotransferase research for the curious. Pharmacogenomics J. 2(5), 297-308 (2002).
38. Zheng L, Wang Y, Schabath MB, Grossman HB, Wu X: Sulfotransferase 1A1 (SULT1A1) polymorphism. and bladder cancer risk. a case-control study. Cancer Lett. 202(1), 61-69 (2003).
39. Arber N, Eagle CJ, Spicak J et al.: Celecoxib for the prevention of colorectal adenomatous polyps. N. Engl. J. Med. 355(9), 885-895 (2006).